Litcius/Paper detail

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, K. OGASAWARA, Timothy R. Mack, Jeremy S Abramson

2022The Lancet752 citationsDOI

Topics & Concepts

MedicineSalvage therapyInternal medicineRituximabTransplantationOncologyHematopoietic stem cell transplantationAutologous stem-cell transplantationSurgeryLymphomaChemotherapyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial | Litcius